Lupus & antiphospholipid syndrome
Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease
Study context
- Population
- Patients with acute exacerbation of ILD associated with connective tissue disease (acute exacerbation of interstitial lung disease (AE-ILD))
- Participants
- 4 patients
- Outcome
- Alive after discharge following exacerbation
- Follow-up
- 30 days after discharge
Main finding
As reported in the abstract
Rituximab
4
events
Observational data: associations, not effects.
Original publication
Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease. RMD Open. Published 6 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →